Baird Financial Group Inc. Has $6.40 Million Stock Holdings in Novo Nordisk A/S $NVO

Baird Financial Group Inc. trimmed its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 58.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 133,537 shares of the company's stock after selling 187,262 shares during the quarter. Baird Financial Group Inc.'s holdings in Novo Nordisk A/S were worth $6,402,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NVO. Hudock Inc. bought a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at approximately $490,000. CORDA Investment Management LLC. lifted its stake in Novo Nordisk A/S by 0.4% in the 2nd quarter. CORDA Investment Management LLC. now owns 418,791 shares of the company's stock valued at $20,077,000 after purchasing an additional 1,867 shares during the last quarter. West Family Investments Inc. boosted its position in Novo Nordisk A/S by 42.5% in the second quarter. West Family Investments Inc. now owns 9,435 shares of the company's stock valued at $452,000 after buying an additional 2,812 shares in the last quarter. Nykredit A S acquired a new stake in Novo Nordisk A/S in the second quarter valued at approximately $289,000. Finally, Parkside Financial Bank & Trust grew its stake in shares of Novo Nordisk A/S by 13.1% during the second quarter. Parkside Financial Bank & Trust now owns 2,436 shares of the company's stock worth $117,000 after buying an additional 283 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy wins China MASH approval: China approved Wegovy for metabolic dysfunction-associated steatohepatitis (MASH), making it the first GLP-1 receptor agonist approved there for the liver disease. The decision expands Wegovy’s addressable market beyond obesity and cardiovascular care and could create an additional long-term growth opportunity. Novo Nordisk Expands Wegovy’s Reach with China MASH Approval
• Positive Sentiment: Oral obesity-drug opportunity remains a potential catalyst: Coverage indicates Novo’s Wegovy pill, launched earlier in 2026, has received a favorable market response, potentially helping the company compete with Eli Lilly’s oral product and regain obesity-market momentum. Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst
• Neutral Sentiment: Corporate rebrand targets a turnaround: Novo Nordisk will use “Novo” as its everyday operating name while retaining its legal name, alongside a new “Lasting Health Starts Now” slogan and “The Novo Way” cultural framework. Management says the changes are intended to improve focus, speed and relevance, but they do not directly change earnings or products. Novo Nordisk rebrands to Novo, unveils corporate changes as it fights for obesity market share
• Positive Sentiment: Share repurchases provide support: Novo continues a repurchase program of up to DKK 15 billion over 12 months, which could support per-share value and signal management confidence. Novo Nordisk A/S - share repurchase programme
• Negative Sentiment: Analyst downgrade highlights major risks: Morgan Stanley cut NVO to Underweight, citing muted growth, patent exposure and intensifying competition from Eli Lilly. Investors remain concerned that Novo must deliver new blockbuster products after a sharp prior decline in the stock. Will Morgan Stanley's NVO downgrade deepen patent and rival woes?

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $43.47 on Tuesday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The stock has a market cap of $194.10 billion, a price-to-earnings ratio of 10.63, a P/E/G ratio of 1.45 and a beta of 0.74. The company's fifty day moving average is $47.37 and its 200 day moving average is $43.71.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%.The business had revenue of $11.98 billion during the quarter. Sell-side analysts forecast that Novo Nordisk A/S will post 3.45 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were given a dividend of $0.5786 per share. This represents a yield of 258.0%. The ex-dividend date of this dividend was Monday, August 17th. Novo Nordisk A/S's dividend payout ratio is currently 19.80%.

Analyst Upgrades and Downgrades

NVO has been the subject of several research analyst reports. Wall Street Zen downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Saturday, June 20th. Deutsche Bank Aktiengesellschaft downgraded Novo Nordisk A/S from a "hold" rating to a "sell" rating in a report on Thursday, August 27th. Zacks Research upgraded Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 11th. Weiss Ratings raised Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, August 5th. Finally, Berenberg Bank set a $47.00 target price on Novo Nordisk A/S in a research report on Wednesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $64.94.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.